The MeCo Score™ is the only clinically validated prognostic and predictive biomarker to identify patients with early-stage breast cancer who may benefit from antifibrotic therapy (1-4).
In effect, our technology has unlocked an entirely new class of therapies for breast cancer.
To maximize its forward compatibility as a companion diagnostic for emergent antifibrotic therapies, the MeCo Score™ is drug-agnostic, pathway-agnostic, and even mechanism-of-action-agnostic. It also demonstrates broad potential for other types of cancer.
As a clinical proof-of-concept, our landmark Phase 2 clinical study demonstrated that patients with High MeCo Score breast tumors who received antifibrotic therapy experienced a remarkable benefit: 62% reduced risk of recurrence over 9.7 years on average (p=0.031) (2,4).
This represents a stunning improvement in the long-term survival rate for a major subgroup of breast cancer patients.
Remarkably, the magnitude and duration of benefit appear to be unprecedented compared to all previous trials of targeted therapies that have ever been evaluated for breast cancer (4,5).
Partnerships & Collaborations
Funding
Affiliations
References
[1] Watson, A.W. et al. (2021). Cell Reports. doi: 10.1016/j.celrep.2021.109293
[2] Quintela-Fandino, M. et al. (2024). Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-24-1518
[3] Mouneimne, G. et al. (2025). Cancers. doi: 10.3390/cancers17101632
[4] Event-free survival (EFS) after antifibrotic therapy (nintedanib) + chemotherapy vs. chemotherapy alone.
[5] Compared to randomized controlled trials that employed a chemotherapy or endocrine therapy backbone and demonstrated statistically significant results.
Note: The prescribing information for the FDA-approved therapy listed in the MeCo Score test report may not include the associated biomarker; the proposed intended use for the MeCo Score test and its cut-off value are subject to change.
*The MeCo Score (TM) assay is for Investigational Use Only
and is not cleared or approved by the US Food and Drug Administration.
Copyright © 2025 MeCo Diagnostics Holdings, Inc. - All Rights Reserved.